Physiomics. Rational Therapeutics

Physiomics plc, the Oxford, UK based systems biology company, is pleased to announce that it will be participating in the 2008 AACR Annual Meeting, taking place in San Diego, on 12-16 April 2008. Dr Eric Fernandez will present a development update on the Company’s chronotherapy research program, as part of the EU funded TEMPO (Temporal Genomics for Tailored Chronotherapeutics) project. The abstract will be published in the 2008 Proceeding of the AACR and will be presented in the poster session “Cellular and Molecular Biology 8”, scheduled for 1:00 pm on 13 April.

Progress for Physiomics.

Physiomics plc, the Oxford, UK based systems biology company, is pleased to announce that it has signed a Memorandum of Understanding (‘MOU’) with the Institute of Life Science of Swansea University, which will provide mutual benefits. Under the terms of the MOU, Physiomics will have access to the Supercomputer “Blue C”, one of the most powerful computers in the world dedicated to Life Science and is the result of a collaboration between the University, the Welsh Assembly Government and computer giant IBM. This will reinforce Physiomics’ modelling framework and help to address the ever increasing computing requirements in the field of System Biology.

ValiRx, the cancer therapeutics company, today announces that Phase 1 of its collaboration with Physiomics plc, the European systems biology simulation company, has been completed. Under the collaboration, originally announced in February 2007, Physiomics’ In Silico simulation technology has been successfully coupled with ValiRx’s GeneICE technology to generate a cancer cell death model – the Apoptosis Model.

Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it has signed an agreement with Eli Lilly and Company (‘Lilly’) (NYSE: LLY), the global pharmaceutical company, to provide in silico simulations of cancer cellular processes in support of Lilly’s cancer drug discovery research.

ValiRx, the cancer therapeutics company, has signed a new agreement with Physiomics to use its in silico simulations of cellular processes to reduce the development time and costs associated in identifying new therapeutic compounds for the treatment of cancers.

Physiomics plc is pleased to announce that it has been selected to participate in the TEMPO (Temporal Genomics for Tailored Chemotherapeutics) Project as one of four Industry partners working closely with four distinguished European academic research groups